TENX Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a pharmaceutical company, which engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its product candidate includes Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
Company profile
Ticker
TENX
Exchange
CEO
Anthony A. DiTonno
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
IQVIA • PRA Health Sciences • Syneos Health • Incyte • Intrexon • Exelixis • ICON • EXACT Sciences • Sorrento Therapeutics • NanoViricides ...
Former names
Oxygen Biotherapeutics, Inc., Synthetic Blood International Inc
SEC CIK
Corporate docs
IRS number
262593535
TENX stock data
()
Calendar
14 Aug 19
21 Aug 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | 1.76M | 1.62M | -18.73M | 1.53M | |
| Diluted EPS | -0.28 | -0.33 | -5.87 | -1.05 | |
| Operating income | 1.82M | 1.66M | -11.56M | 1.55M | |
| Net change in cash | -1.91M | -2.05M | 9.02M | -555.7K | |
| Cash on hand | 8.41M | 10.32M | 12.37M | 3.35M | |
| Cost of revenue |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 0 | ||||
| Net income | -14.14M | -8.84M | -43.92M | ||
| Diluted EPS | -9.04 | -6.27 | -31.24 | ||
| Operating income | -6.89M | -9.21M | -52.65M | ||
| Net change in cash | 2.87M | -12.4M | -16.3M | ||
| Cash on hand | 12.37M | 9.5M | 21.9M | 38.2M | |
| Cost of revenue | 0 |
Financial data from company earnings reports
Financial report summary
?Competition
CytokineticsManagement Discussion
- Cash and cash equivalents, including the fair-value of our marketable securities, were $8.9 million at June 30, 2019.
- Our net loss from operations was $1.8 million for the second quarter of fiscal 2019 compared to $1.9 million for the three months ended June 30, 2018.
- Net cash used in operating activities was $1.9 million and $1.2 million for the three months ended June 30, 2019 and 2018, respectively.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
advisory, arbitration, attached, correct, declaration, deteriorate, disagreement, dispute, economic, entirety, Finnish, firm, inconsistent, interpretation, line, oral, outreach, proxy, reimburse, rejected, relationship, rely, request, requested, resolved, response, scientific, shareholder, solicitation, strain
Removed:
connection
Financial reports
10-Q
2019 Q2
Quarterly report
14 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
1 Apr 19
10-Q
2018 Q3
Quarterly report
14 Nov 18
10-Q
2018 Q2
Quarterly report
14 Aug 18
10-Q
2018 Q1
Quarterly report
15 May 18
10-K
2017 FY
Annual report
2 Apr 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
9 Aug 17
10-Q
2017 Q1
Quarterly report
10 May 17
Current reports
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 19
8-K
Tenax Therapeutics Announces Closing of
11 Dec 18
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 18
8-K
Tenax Therapeutics Announces Appointment of
5 Jun 18
8-K
Other Events
14 Mar 18
8-K
Tenax Therapeutics Announces Reverse Stock Split
23 Feb 18
8-K
Submission of Matters to a Vote of Security Holders
15 Feb 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Sep 17
8-K
Tenax Therapeutics Provides Regulatory Update on Levosimendan
28 Jul 17
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 17
Registration and prospectus
424B4
Prospectus supplement with pricing info
7 Dec 18
S-1/A
IPO registration (amended)
6 Dec 18
S-1/A
IPO registration (amended)
3 Dec 18
FWP
Free writing prospectus
20 Nov 18
S-1/A
IPO registration (amended)
20 Nov 18
S-1
IPO registration
6 Nov 18
S-3
Shelf registration
15 May 18
S-8
Registration of securities for employees
3 Apr 18
S-8
Registration of securities for employees
14 Mar 16
S-3
Shelf registration
24 Feb 15
Proxies
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
20 Apr 18
DEF 14A
Definitive proxy
16 Jan 18
PRE 14A
Preliminary proxy
29 Dec 17
DEF 14A
Definitive proxy
28 Apr 17
DEF 14A
Definitive proxy
26 Apr 16
DEF 14A
Definitive proxy
17 Aug 15
DEF 14A
Definitive proxy
12 Aug 14
PRE 14A
Preliminary proxy
31 Jul 14
DEF 14A
Definitive proxy
4 Feb 14
Other
EFFECT
Notice of effectiveness
10 Dec 18
EFFECT
Notice of effectiveness
24 May 18
UPLOAD
Letter from SEC
22 May 18
CORRESP
Correspondence with SEC
21 May 18
CORRESP
Correspondence with SEC
6 Mar 15
EFFECT
Notice of effectiveness
6 Mar 15
CORRESP
Correspondence with SEC
3 Mar 15
UPLOAD
Letter from SEC
26 Feb 15
EFFECT
Notice of effectiveness
8 Sep 14
EFFECT
Notice of effectiveness
13 Jun 14